Skip to main content
Top
Published in: Supportive Care in Cancer 6/2013

01-06-2013 | Original Article

A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment

Authors: Carolyn Miller Reilly, Deborah Watkins Bruner, Sandra A. Mitchell, Lori M. Minasian, Ethan Basch, Amylou C. Dueck, David Cella, Bryce B. Reeve

Published in: Supportive Care in Cancer | Issue 6/2013

Login to get access

Abstract

Purpose

Patients with cancer experience acute and chronic symptoms caused by their underlying disease or by the treatment. While numerous studies have examined the impact of various treatments on symptoms experienced by cancer patients, there are inconsistencies regarding the symptoms measured and reported in treatment trials. This article presents a systematic review of the research literature of the prevalence and severity of symptoms in patients undergoing cancer treatment.

Methods

A systematic search for studies of persons receiving active cancer treatment was performed with the search terms of “multiple symptoms” and “cancer” for studies involving patients over the age of 18 years and published in English during the years 2001 to 2011. Search outputs were reviewed independently by seven authors, resulting in the synthesis of 21 studies meeting criteria for generation of an Evidence Table reporting symptom prevalence and severity ratings.

Results

Data were extracted from 21 multi-national studies to develop a pooled sample of 4,067 cancer patients in whom the prevalence and severity of individual symptoms was reported. In total, the pooled sample across the 21 studies was comprised of 62 % female, with a mean age of 58 years (range 18 to 97 years). A majority (62 %) of these studies assessed symptoms in homogeneous samples with respect to tumor site (predominantly breast and lung cancer), while 38 % of the included studies utilized samples with mixed diagnoses and treatment regimens. Eighteen instruments and structured interviews were including those measuring single symptoms, multi-symptom inventories, and single symptom items drawn from HRQOL or health status measures. The MD Anderson Symptom Inventory was the most commonly used instrument in the studies analyzed (n = 9 studies; 43 %), while the Functional Assessment of Cancer Therapy, Hospital Anxiety and Depression Subscale, Medical Outcomes Survey Short Form-36, and Symptom Distress Scale were each employed in two studies. Forty-seven symptoms were identified across the 21 studies which were then categorized into 17 logical groupings. Symptom prevalence and severity were calculated across the entire cohort and also based upon sample sizes in which the symptoms were measured providing the ability to rank symptoms.

Conclusions

Symptoms are prevalent and severe among patients with cancer. Therefore, any clinical study seeking to evaluate the impact of treatment on patients should consider including measurement of symptoms. This study demonstrates that a discrete set of symptoms is common across cancer types. This set may serve as the basis for defining a “core” set of symptoms to be recommended for elicitation across cancer clinical trials, particularly among patients with advanced disease.
Literature
1.
go back to reference Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30(16):1980–1988PubMedCrossRef Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS (2012) Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 30(16):1980–1988PubMedCrossRef
2.
go back to reference Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362(10):865–869PubMedCrossRef Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362(10):865–869PubMedCrossRef
3.
go back to reference Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA (2011) How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Med Decis Makin 31(3):380–385CrossRef Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA (2011) How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Med Decis Makin 31(3):380–385CrossRef
4.
go back to reference Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9(3):186–187PubMedCrossRef Kirkbride P, Tannock IF (2008) Trials in palliative treatment—have the goal posts been moved? Lancet Oncol 9(3):186–187PubMedCrossRef
5.
go back to reference Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632PubMedCrossRef Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101(23):1624–1632PubMedCrossRef
6.
go back to reference Kagan KO, Schmidt M, Kuhn U, Kimmig R (2004) Ventricular outflow obstruction, valve aplasia, bradyarrhythmia, pulmonary hypoplasia and non-immune fetal hydrops because of a large rhabdomyoma in a case of unknown tuberous sclerosis: a prenatal diagnosed cardiac rhabdomyoma with multiple symptoms. BJOG: Int J Obstet Gynaecol 111(12):1478–1480. doi:10.1111/j.1471-0528.2004.00271.x CrossRef Kagan KO, Schmidt M, Kuhn U, Kimmig R (2004) Ventricular outflow obstruction, valve aplasia, bradyarrhythmia, pulmonary hypoplasia and non-immune fetal hydrops because of a large rhabdomyoma in a case of unknown tuberous sclerosis: a prenatal diagnosed cardiac rhabdomyoma with multiple symptoms. BJOG: Int J Obstet Gynaecol 111(12):1478–1480. doi:10.​1111/​j.​1471-0528.​2004.​00271.​x CrossRef
7.
go back to reference Chen SQ, Zou SQ, Dai QB, Li H (2008) Clinical analysis of solid-pseudopapillary tumor of the pancreas: report of 15 cases. Hepatobiliary Pancreat Dis Int 7(2):196–200PubMed Chen SQ, Zou SQ, Dai QB, Li H (2008) Clinical analysis of solid-pseudopapillary tumor of the pancreas: report of 15 cases. Hepatobiliary Pancreat Dis Int 7(2):196–200PubMed
12.
go back to reference Rischer J, Scherwath A, Zander AR, Koch U, Schulz-Kindermann F (2009) Sleep disturbances and emotional distress in the acute course of hematopoietic stem cell transplantation. Bone Marrow Transplant 44(2):121–128. doi:10.1038/bmt.2008.430 PubMedCrossRef Rischer J, Scherwath A, Zander AR, Koch U, Schulz-Kindermann F (2009) Sleep disturbances and emotional distress in the acute course of hematopoietic stem cell transplantation. Bone Marrow Transplant 44(2):121–128. doi:10.​1038/​bmt.​2008.​430 PubMedCrossRef
16.
go back to reference Singh Y, Vaidya P, Hemandas AK, Singh KP, Khakurel M (2002) Colorectal carcinoma in Nepalese young adults: presentation and outcome. Gan To Kagaku Ryoho 29(Suppl 1):223–229PubMed Singh Y, Vaidya P, Hemandas AK, Singh KP, Khakurel M (2002) Colorectal carcinoma in Nepalese young adults: presentation and outcome. Gan To Kagaku Ryoho 29(Suppl 1):223–229PubMed
18.
go back to reference Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101(10):2170–2176. doi:10.1002/cncr.20594 PubMedCrossRef Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E, Mailliard JA (2004) Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101(10):2170–2176. doi:10.​1002/​cncr.​20594 PubMedCrossRef
20.
go back to reference Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerstrom J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL (2006) Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 91(9):1228–1233PubMed Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisloff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerstrom J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL (2006) Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 91(9):1228–1233PubMed
22.
go back to reference Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C (2002) Putting cancer pain management regimens into practice at home. J Pain Symptom Manag 23(5):369–382CrossRef Schumacher KL, Koresawa S, West C, Hawkins C, Johnson C, Wais E, Dodd M, Paul SM, Tripathy D, Koo P, Miaskowski C (2002) Putting cancer pain management regimens into practice at home. J Pain Symptom Manag 23(5):369–382CrossRef
23.
24.
go back to reference Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag 23(5):442–447CrossRef Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD (2002) An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag 23(5):442–447CrossRef
30.
go back to reference Avery KNL, Metcalfe C, Barham CP, Alderson D, Falk SJ, Blazeby JM (2007) Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg 94(11):1369–1376. doi:10.1002/bjs.5888 PubMedCrossRef Avery KNL, Metcalfe C, Barham CP, Alderson D, Falk SJ, Blazeby JM (2007) Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg 94(11):1369–1376. doi:10.​1002/​bjs.​5888 PubMedCrossRef
31.
go back to reference Bhavnani SK, Bellala G, Ganesan A, Krishna R, Saxman P, Scott C, Silveira M, Given C (2010) The nested structure of cancer symptoms. Implications for analyzing co-occurrence and managing symptoms. Methods Inf Med 49(6):581–591. doi:10.3414/me09-01-0083 PubMedCrossRef Bhavnani SK, Bellala G, Ganesan A, Krishna R, Saxman P, Scott C, Silveira M, Given C (2010) The nested structure of cancer symptoms. Implications for analyzing co-occurrence and managing symptoms. Methods Inf Med 49(6):581–591. doi:10.​3414/​me09-01-0083 PubMedCrossRef
33.
go back to reference Miaskowski C, Cooper BA, Paul SM, Dodd M, Lee K, Aouizerat BE, West C, Cho M, Bank A (2006) Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum 33(5):E79–89. doi:10.1188/06.onf.e79-e89 PubMedCrossRef Miaskowski C, Cooper BA, Paul SM, Dodd M, Lee K, Aouizerat BE, West C, Cho M, Bank A (2006) Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum 33(5):E79–89. doi:10.​1188/​06.​onf.​e79-e89 PubMedCrossRef
34.
go back to reference Saitoh E, Yokomizo Y, Chang CH, Eremenco S, Kaneko H, Kobayashi K (2007) Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. J Nihon Med Sch 74(6):402–408CrossRef Saitoh E, Yokomizo Y, Chang CH, Eremenco S, Kaneko H, Kobayashi K (2007) Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. J Nihon Med Sch 74(6):402–408CrossRef
37.
go back to reference Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee B-N, Giralt SA (2008) Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102–2109. doi:10.1002/cncr.23820 PubMedCrossRef Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, Lee B-N, Giralt SA (2008) Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 113(8):2102–2109. doi:10.​1002/​cncr.​23820 PubMedCrossRef
38.
39.
go back to reference Gift AG, Stommel M, Jablonski A, Given W (2003) A cluster of symptoms over time in patients with lung cancer. Nurs Res 52(6):393–400PubMedCrossRef Gift AG, Stommel M, Jablonski A, Given W (2003) A cluster of symptoms over time in patients with lung cancer. Nurs Res 52(6):393–400PubMedCrossRef
40.
go back to reference Anderson KO, Giralt SA, Mendoza TR, Brown JO, Neumann JL, Mobley GM, Wang XS, Cleeland CS (2007) Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 39(12):759–766. doi:10.1038/sj.bmt.1705664 PubMedCrossRef Anderson KO, Giralt SA, Mendoza TR, Brown JO, Neumann JL, Mobley GM, Wang XS, Cleeland CS (2007) Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 39(12):759–766. doi:10.​1038/​sj.​bmt.​1705664 PubMedCrossRef
41.
42.
go back to reference Chen ML, Chang HK (2004) Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med 18(8):712–718PubMedCrossRef Chen ML, Chang HK (2004) Physical symptom profiles of depressed and nondepressed patients with cancer. Palliat Med 18(8):712–718PubMedCrossRef
44.
go back to reference Ferreira KASL, Kimura M, Teixeira MJ, Mendoza TR, da Nóbrega JCM, Graziani SR, Takagaki TY (2008) Impact of cancer-related symptom synergisms on health-related quality of life and performance status. J Pain Symptom Manag 35(6):604–616. doi:10.1016/j.jpainsymman.2007.07.010 CrossRef Ferreira KASL, Kimura M, Teixeira MJ, Mendoza TR, da Nóbrega JCM, Graziani SR, Takagaki TY (2008) Impact of cancer-related symptom synergisms on health-related quality of life and performance status. J Pain Symptom Manag 35(6):604–616. doi:10.​1016/​j.​jpainsymman.​2007.​07.​010 CrossRef
46.
go back to reference Harding G, Cella D, Robinson D, Mahadevia PJ, Clark J, Revicki DA (2007) Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5(1):34. doi:10.1186/1477-7525-5-34 PubMedCrossRef Harding G, Cella D, Robinson D, Mahadevia PJ, Clark J, Revicki DA (2007) Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5(1):34. doi:10.​1186/​1477-7525-5-34 PubMedCrossRef
47.
go back to reference Hayes SC, Rye S, Battistutta D, Newman B (2010) Prevalence of upper-body symptoms following breast cancer and its relationship with upper-body function and lymphedema. Lymphology 43(4):178–187PubMed Hayes SC, Rye S, Battistutta D, Newman B (2010) Prevalence of upper-body symptoms following breast cancer and its relationship with upper-body function and lymphedema. Lymphology 43(4):178–187PubMed
53.
go back to reference Kiteley CA, Fitch MI (2006) Understanding the symptoms experienced by individuals with lung cancer. Can Oncol Nurs J 16(1):25–36PubMed Kiteley CA, Fitch MI (2006) Understanding the symptoms experienced by individuals with lung cancer. Can Oncol Nurs J 16(1):25–36PubMed
55.
go back to reference Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C (2007) Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manag 34(3):244–252. doi:10.1016/j.jpainsymman.2006.11.007 CrossRef Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolff RA, Crane C (2007) Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manag 34(3):244–252. doi:10.​1016/​j.​jpainsymman.​2006.​11.​007 CrossRef
59.
go back to reference Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, Johnson VE (2010) Impact of cultural and linguistic factors on symptom reporting by patients with cancer. JNCI J Natl Cancer Inst 102(10):732–738. doi:10.1093/jnci/djq097 CrossRef Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, Johnson VE (2010) Impact of cultural and linguistic factors on symptom reporting by patients with cancer. JNCI J Natl Cancer Inst 102(10):732–738. doi:10.​1093/​jnci/​djq097 CrossRef
60.
go back to reference Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS (2010) Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 116(8):2053–2063. doi:10.1002/cncr.24920 PubMedCrossRef Wang XS, Williams LA, Eng C, Mendoza TR, Shah NA, Kirkendoll KJ, Shah PK, Trask PC, Palos GR, Cleeland CS (2010) Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer 116(8):2053–2063. doi:10.​1002/​cncr.​24920 PubMedCrossRef
Metadata
Title
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment
Authors
Carolyn Miller Reilly
Deborah Watkins Bruner
Sandra A. Mitchell
Lori M. Minasian
Ethan Basch
Amylou C. Dueck
David Cella
Bryce B. Reeve
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1688-0

Other articles of this Issue 6/2013

Supportive Care in Cancer 6/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine